Revolution Medicines, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Revolution Medicines, Inc. (RVMD) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 28.23 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 27.07M shares, a 16.36% increase year-over-year.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 23.27M shares, a 14.37% increase year-over-year.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 20.34M shares, a 60.46% increase year-over-year.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 12.68M shares, a 37.56% increase year-over-year.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 24.51M shares, a 26.15% increase from fiscal 2024.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 19.43M shares, a 16.74% increase from fiscal 2023.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 16.64M shares, a 71.15% increase from fiscal 2022.
- Revolution Medicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.72M shares, a 45.56% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 28.23M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 27.07M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 24.51M shares 10-K · filed 2026-02-25 | |||
| 2025-09-30 | 24.23M shares 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 23.97M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 23.27M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 19.43M shares 10-K · filed 2026-02-25 | |||
| 2024-09-30 | 20.57M shares 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 20.42M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 20.34M shares 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 16.64M shares 10-K · filed 2026-02-25 | |||
| 2023-09-30 | 13.32M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 13.05M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 12.68M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 9.72M shares 10-K · filed 2025-02-26 | |||
| 2022-09-30 | 9.88M shares 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | 9.53M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 9.22M shares 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 6.68M shares 10-K · filed 2024-02-26 | |||
| 2021-09-30 | 6.63M shares 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | 6.61M shares 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 6.43M shares 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 5.43M shares 10-K · filed 2023-02-27 | |||
| 2020-09-30 | 5.67M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 6.08M shares 10-Q · filed 2020-08-10 | 6.08M shares 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | 5.86M shares 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | 44.87M shares 10-K · filed 2022-02-28 | |||
| 2019-09-30 | 44.70M shares 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 41.83M shares 10-Q · filed 2020-08-10 | 41.83M shares 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | 28.96M shares 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | 31.84M shares 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |